
A little over 25 years ago a paper was published in the journal Science showing that BHT, a common food preservative, could inactivate herpes simplex and other lipid-coated viruses in lab dishes 1. Two years later another paper in the same journal reported similar results, but this time in live animals — dietary BHT could prevent chickens from dying of Newcastle disease 2. Like herpes simplex, NDV (the virus that causes Newcastle disease) is lipid-enveloped — its nucleic acid core is sheathed in a fatty membrane. Viruses of this type require an intact membrane to be infective. BHT seems to work against such viruses by disrupting their viral membranes.
In the chicken study cited above, the amount of BHT needed to inhibit NDV turned out to be equal to the amount already present in chicken feed as an additive, i.e., 100 to 200 parts per million of total diet 2. Assuming a comparable result for humans and a total food intake of about 2 kilograms per day, this would mean that 200 to 400 milligrams of BHT ingested daily should be adequate to protect most people from infection by herpes and other lipid-coated viruses.
Inspired by early scientific reports on the antiviral activity of BHT, a number of people suffering from herpes began to experiment on themselves in the late 1970s. As described in several books published a few years later, the BHT experimenters discovered that a daily dose of 250 to 1000 mg resulted in rapid recovery from herpes eruptions with no recurrences 3, 4.
Studies performed since then have confirmed the activity of BHT against many different human and animal viruses, including such members of the herpes family as CMV (cytomegalovirus) 5, pseudorabies 6 and genital herpes 7. BHT appears to inhibit infectivity of HIV 8, the AIDS virus, although contradictory results have also been reported 9. A protective effect of BHT against the development of influenza infection has been shown 10, 11. The mechanism involved may have to do with the fact that BHT is a highly potent, membrane-active antioxidant as well as a membrane fluidizer. It’s known that reactive oxygen species (ROS) play a role in the pathogenesis of viral infections — including RNA viruses such as influenza, DNA viruses such as hepatitis B, and retroviruses such as HIV — and it’s been suggested that antioxidants may be useful as therapeutic agents in such infections 12.
If BHT is so effective against lipid-enveloped viruses, why don’t doctors prescribe it for their patients? The answer is that almost none of the controlled studies on the antiviral properties of BHT have been performed on humans; most of the experiments thus far have been conducted in lab dishes (in vitro) or in animals. A human clinical trial of BHT cannot be performed because the Food and Drug Administration (FDA) has approved BHT for use only as a food preservative, not as a medicine 4. But that hasn’t stopped some people from using BHT on their own to treat herpes or other viral conditions.
In the past, safety concerns have been sometimes raised about BHT because of its reputed toxicity when given to rats in massive doses — doses much larger than those usually consumed for their antiviral effect. On the other hand, 25 years is long enough for any adverse effects as well as positive benefits to have shown up in humans. Many individuals — including my friend Roger, whom I’ve known since high school — have been supplementing with BHT on a regular basis for years at a time. Roger looks pretty healthy to me these days, but I phoned him anyway to press him for details on his BHT experience.
Roger first began taking BHT in 1984 after reading about it in Pearson and Shaw’s groundbreaking book 3. Initially he took about 1 gram per day because he was buying BHT in bulk at the time and larger amounts were easier to measure out than smaller ones. Later he was able to obtain BHT in capsules containing 250 mg per cap, and from that point on he took 250 mg every day for 6 to 7 years. Not surprisingly, during this period he remained completely free of herpes eruptions. More surprising is that he still remains herpes-free to this day, 10 years after his last dose of BHT. Around 3 years ago Roger had a comprehensive physical exam, including blood work. His physician told him that no antibodies to the herpes simplex virus could be found in his system.
Today Roger’s health is generally excellent, with no indication that his years of supplementing with BHT have harmed him in any way. The only adverse effect he ever encountered happened early on, while he was still experimenting with the size of the dose. Roger found that taking 3 grams of BHT each day resulted in dizziness and disorientation, which quickly disappeared when he cut his dose back to 1 gram per day. No adverse effects were seen thereafter.
Of course, a sample of one doesn’t constitute much of a survey. I needed to consult a larger database, so I turned to Steven Fowkes, resident guru at the Cognitive Enhancement Research Institute (CERI) in Menlo Park, California and co-author of Wipe Out Herpes with BHT 4. Steve Fowkes was unequivocal in his judgment. In the decades since BHT first arrived on the supplement scene, Steve hasn’t heard of any adverse reactions other than two minor ones. First, BHT can cause hives in some people who are sensitive to it. Second, BHT can cause a temporary decrease in blood clotting when people first begin taking it in substantial doses.
Allergic sensitivities to food additives such as dyes and preservatives have been known for some time but the role of these additives in precipitating chronic urticaria (hives) or other symptoms is still a matter of debate 13, 14. Only a few cases over the years have identified low-level BHT intake as the sole cause of hives 15, 16, so this reaction is not likely to be very common; however, it may well become more common if provoked by large doses of BHT. Fortunately, the condition tends to clear up after BHT use is halted.
As for the transient blood-thinning effect, Steve cautioned that people who have never taken BHT before should acclimatize themselves by starting out with small doses (less than 250 mg for the first day, if possible) and ramping up gradually over the course of a week; there is a special need for caution among those who are taking anticoagulants at the same time. In no case should the final dose exceed 1 gram per day without medical supervision. BHT’s anticlotting effect will diminish within 2 days in any event, unless extremely high doses (around 5 grams per day or higher) are being taken.
But what about liver toxicity? BHT gets metabolized in the liver, so won’t taking large amounts compromise liver function? Steve’s response was that he has spoken with literally hundreds of people who have successfully treated themselves for herpes with BHT. So long as a dose level of 1 gram per day was not exceeded, no cases of hepatic injury (as determined by pathologically high serum levels of the liver enzymes ALT and AST) have yet been reported by this group.
Unfortunately, some people taking BHT will find that not even 1 gram per day is sufficient to eradicate herpes. Rather than increasing the dose to more than a gram per day, Steve suggests maintaining the BHT level while combining it with other supplements. For example, the combination of BHT with hypericin (from St. John’s Wort) is a synergistic antiviral combination, more effective than BHT alone. To determine an appropriate dose level, hypericin intake should be ramped up gradually from 1 mg per day until an effective dose is reached, usually 10 mg per day or less. Steve also recommended pulsing the hypericin at the effective dose level, i.e., using it for about a week at a time with time off between dosing episodes. Because hypericin can cause photosensitivity of the skin, sun exposure should be limited to half the usual daily amount during and after hypericin intake. One of the nice features of BHT is that it tends to inhibit any oxidative stress induced by hypericin; for this reason, Steve feels that anyone taking hypericin should always take BHT with it. (For more information on hypericin, see the reference articles on the LifeLink website.)
After talking with Steve Fowkes and reviewing the scientific literature, I’ve concluded that the benefits of taking BHT seem to greatly outweigh the risks. In the process of researching this article I was reminded of a fundamental principle of toxicology first enunciated around 500 years ago by Paracelsus, the great Renaissance physician and alchemist: “All substances are poisons; there is none which is not a poison. The correct dose differentiates a poison from a remedy.” Or in the present case, “the correct dose differentiates a remedy from a food additive.”
References
[1] Snipes W, Person S, Keith A, Cupp J. Butylated hydroxytoluene inactivates lipid-containing viruses. Science. 1975;188(4183):64-6.
[2] Brugh M Jr. Butylated hydroxytoluene protects chickens exposed to Newcastle disease virus. Science. 1977;197(4310):1291-2.
[3] Pearson D, Shaw S. Life Extension: A Practical Scientific Approach. New York, NY: Warner Books, Inc.; 1982:206-207.
[4] Mann JA, Fowkes SW. Wipe Out Herpes with BHT. Manhattan Beach, Calif: MegaHealth Society; 1983.
[5] Kim KS, Moon HM, Sapienza V, Carp RI, Pullarkat R. Inactivation of cytomegalovirus and Semliki Forest virus by butylated hydroxytoluene. J Infect Dis 1978;138(1):91-4.
[6] Pirtle EC, Sacks JM, Nachman RJ. Antiviral effectiveness of butylated hydroxytoluene against pseudorabies (Aujeszky’s disease) virus in cell culture, mice, and swine. Am J Vet Res. 1986;47(9):1892-5.
[7] Richards JT, Katz ME, Kern ER. Topical butylated hydroxytoluene treatment of genital herpes simplex virus infections of guinea pigs. Antiviral Res 1985;5(5):281-90.
[8] Aloia RC, Jensen FC, Curtain CC, Mobley PW, Gordon LM. Lipid composition and fluidity of the human immunodeficiency virus. Proc Natl Acad Sci U S A 1988;85(3):900-4.
[9] Claeys H, Mercken M, Vermylen C. HIV1-virus is not inactivated by buthylated hydroxytoluene (BHT) in vitro. Med Hypotheses 1988;27(2):145-6.
[10] Chetverikova LK, Ki’ldivatov II, Inozemtseva LI, Kramskaia TA, Filippov VK, Frolov BA. Factors of antiviral resistance in the pathogenesis of influenza in mice [in Russian]. Vestn Akad Med Nauk SSSR 1989;(11):63-8.
[11] Chetverikova LK, Inozemtseva LI. Role of lipid peroxidation in the pathogenesis of influenza and search for antiviral protective agents [in Russian]. Vestn Ross Akad Med Nauk 1996;(3):37-40.
[12] Schwarz KB. Oxidative stress during viral infection: a review. Free Radic Biol Med 1996;21(5):641-9.
[13] Hannuksela M, Lahti A. Peroral challenge tests with food additives in urticaria and atopic dermatitis. Int J Dermatol 1986;25(3):178-80.
[14] Reus KE, Houben GF, Stam M, Dubois AE. Food additives as a cause of medical symptoms: relationship shown between sulfites and asthma and anaphylaxis; results of a literature review [in Dutch]. Ned Tijdschr Geneeskd 2000;144(38):1836-9.
[15] Moneret-Vautrin DA, Faure G, Bene MC. Chewing-gum preservative induced toxidermic vasculitis. Allergy 1986;41(7):546-8.
[16] Goodman DL, McDonnell JT, Nelson HS, Vaughan TR, Weber RW. Chronic urticaria exacerbated by the antioxidant food preservatives, butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT). J Allergy Clin Immunol 1990;86(4 pt 1):570-5.
[17] [No authors listed.] Butylated hydroxytoluene (BHT). IARC Monogr Eval Carcinog Risk Chem Hum 1986;40:161-206.
[18] Ames BN, Gold LS. Chemical carcinogenesis: too many rodent carcinogens. Proc Natl Acad Sci U S A 1990;87(19):7772-6. Full text accessible at http://socrates.berkeley.edu/mutagen//ames.PNASI.html.
[19] Kensler TW, Egner PA, Trush MA, Bueding E, Groopman JD. Modification of aflatoxin B1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiothione. Carcinogenesis 1985;6(5):759-63.
[20] Williams GM, Iatropoulos MJ. Inhibition of the hepatocarcinogenicity of aflatoxin B1 in rats by low levels of the phenolic antioxidants butylated hydroxyanisole and butylated hydroxytoluene. Cancer Lett 1996;104(1):49-53.
[21] McKee RH, Tometsko AM. Inhibition of promutagen activation by the antioxidants butylated hydroxyanisole and butylated hydroxytoluene. J Natl Cancer Inst 1979;63(2):473-7.
[22] Franklin RA. Butylated hydroxytoluene in sarcoma-prone dogs. Lancet 1976;1(7972):1296.